Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma.

Turkington RC, Knight LA, Blayney JK, Secrier M, Douglas R, Parkes EE, Sutton EK, Stevenson L, McManus D, Halliday S, McCavigan AM, Logan GE, Walker SM, Steele CJ, Perner J, Bornschein J, MacRae S, Miremadi A, McCarron E, McQuaid S, Arthur K, James JA, Eatock MM, O'Neill R, Noble F, Underwood TJ, Harkin DP, Salto-Tellez M, Fitzgerald RC, Kennedy RD; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group.

Gut. 2019 Nov;68(11):1918-1927. doi: 10.1136/gutjnl-2018-317624. Epub 2019 Mar 9.

2.

A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract.

Graham JS, Boyd K, Coxon FY, Wall LR, Eatock MM, Maughan TS, Highley M, Soulis E, Harden S, Bützberger-Zimmerli P, Evans TR.

BMC Res Notes. 2016 Mar 12;9:161. doi: 10.1186/s13104-015-1778-4.

3.

Clinical tumor staging of adenocarcinoma of the esophagus and esophagogastric junction.

Turkington RC, Parkes E, Kennedy RD, Eatock MM, Harrison C, McCloskey P, Purcell C.

J Clin Oncol. 2015 Mar 20;33(9):1088. doi: 10.1200/JCO.2014.59.2402. Epub 2015 Feb 2. No abstract available.

PMID:
25646194
4.

A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma.

Turkington RC, Purcell C, James CR, Millar J, Napier E, Law D, Gallagher R, Morris M, Wilson RH, Eatock MM.

Invest New Drugs. 2014 Apr;32(2):250-60. doi: 10.1007/s10637-013-9970-7. Epub 2013 May 11.

PMID:
23665866
5.

Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer.

Eatock MM, Tebbutt NC, Bampton CL, Strickland AH, Valladares-Ayerbes M, Swieboda-Sadlej A, Van Cutsem E, Nanayakkara N, Sun YN, Zhong ZD, Bass MB, Adewoye AH, Bodoky G.

Ann Oncol. 2013 Mar;24(3):710-8. doi: 10.1093/annonc/mds502. Epub 2012 Oct 28.

PMID:
23108953
6.

A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors.

Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, Arkenau HT, Moreno-Farre J, Banerji U, Roels B, Peachey H, Aherne W, de Bono JS, Raynaud F, Workman P, Judson I.

Clin Cancer Res. 2011 Mar 15;17(6):1561-70. doi: 10.1158/1078-0432.CCR-10-1927. Epub 2011 Jan 28. Erratum in: Clin Cancer Res. 2018 Nov 1;24(21):5488.

7.

Predictive and prognostic markers in colorectal cancer.

Turkington RC, Coyle VM, Johnston PG, Eatock MM.

Per Med. 2007 Aug;4(3):295-306. doi: 10.2217/17410541.4.3.295.

PMID:
29788671
8.

Cholethorax following percutaneous transhepatic biliary drainage.

Turkington RC, Leggett JJ, Hurwitz J, Eatock MM.

Ulster Med J. 2007 May;76(2):112-3. No abstract available.

9.

A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma.

Jones RJ, Hawkins RE, Eatock MM, Ferry DR, Eskens FA, Wilke H, Evans TR.

Cancer Chemother Pharmacol. 2008 Mar;61(3):435-41. Epub 2007 Apr 18.

PMID:
17440725
10.
11.

Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver.

Sharma RA, Eatock MM, Twelves CJ, Brown G, McLelland HR, Clayton KT, O'Byrne KJ, Moyses C, Carmichael J, Steward WP.

Cancer Chemother Pharmacol. 2001 Sep;48(3):197-201.

PMID:
11592340
12.

A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma.

Eatock MM, Anthony DA, El-Abassi M, Wilson P, Paul J, Smith M, Soukop M, Evans TR.

Br J Cancer. 2000 Jun;82(12):1925-31.

13.

Tumour vasculature as a target for anticancer therapy.

Eatock MM, Schätzlein A, Kaye SB.

Cancer Treat Rev. 2000 Jun;26(3):191-204. Review.

PMID:
10814561
14.

Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin's disease. West of Scotland Lymphoma Group.

Dunlop DJ, Eatock MM, Paul J, Anderson S, Reed NS, Soukop M, Lucie N, Fitzsimmons EJ, Tansey P, Steward WP.

Clin Oncol (R Coll Radiol). 1998;10(2):107-14.

PMID:
9610900
15.

Bioavailability of subcutaneous 5-fluorouracil: a case report.

Eatock MM, Carlin W, Dunlop DJ, Soukop M, Watson DG.

Cancer Chemother Pharmacol. 1996;38(1):110-2.

PMID:
8603444

Supplemental Content

Loading ...
Support Center